Showing results (11-20 of 333) with videos related to
Sort By:
Pageof 34
Basic & Clinical Pharmacology & Toxicology|April 3, 2014
The impact of NSAID treatment on cardiovascular risk - insight from Danish observational dataAnne-Marie Schjerning Olsen, Emil L Fosbøl, Gunnar H GislasonActa Dermato-Venereologica|May 4, 2016
Prognosis after Hospitalization for ErythrodermaAlexander Egeberg, Jacob P Thyssen, Gunnar H Gislason, et al.Expert Opinion on Drug Safety|June 24, 2010
Cardiovascular safety of non-steroidal anti-inflammatory drugs among healthy individualsEmil Loldrup Fosbøl, Lars Køber, Christian Torp-Pedersen, et al.The Journal of Cardiovascular Nursing|December 26, 2007
Use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs in high doses increases mortality and risk of reinfarction in patients with prior myocardial infarctionRikke Sørensen, Steen Z Abildstrom, Christian Torp-Pedersen, et al.Annals of Neurology|April 29, 2016
Patients with rosacea have increased risk of dementiaAlexander Egeberg, Peter R Hansen, Gunnar H Gislason, et al.Cancer Epidemiology|January 30, 2017
Rosacea and risk of cancer in DenmarkAlexander Egeberg, Joseph F Fowler, Gunnar H Gislason, et al.JAMA Dermatology|January 29, 2016
Association of Rosacea With Risk for Glioma in a Danish Nationwide Cohort StudyAlexander Egeberg, Peter R Hansen, Gunnar H Gislason, et al.American Journal of Clinical Dermatology|August 3, 2016
Nationwide Assessment of Cause-Specific Mortality in Patients with Rosacea: A Cohort Study in DenmarkAlexander Egeberg, Joseph F Fowler, Gunnar H Gislason, et al.JAMA Neurology|March 22, 2016
Exploring the Association Between Rosacea and Parkinson Disease: A Danish Nationwide Cohort StudyAlexander Egeberg, Peter Riis Hansen, Gunnar H Gislason, et al.Journal of the American Academy of Dermatology|July 23, 2016
Assessment of the risk of cardiovascular disease in patients with rosaceaAlexander Egeberg, Peter R Hansen, Gunnar H Gislason, et al.Pageof 34